Immune checkpoint inhibitor myocarditis: a systematic case study
https://doi.org/10.15829/29/1560-4071-2020-3910
Abstract
Myocarditis is a life-threatening complication of immune checkpoint inhibitor therapy. Over the past ten years, drugs in this group have been used in the treatment of a wide range of hematological diseases and solid tumors. With steadily growing life expectancy of cancer patients, problems associated with treatment complications are increasingly coming to the fore. Since 2016, publications have appeared on cases of autoimmune myocarditis during checkpoint inhibitor therapy (CIT), among which there are quite a few single-center retrospective and observational studies. At the same time, the problem of diagnosis and treatment of immune checkpoint inhibitor myocarditis remains unresolved.
This paper presents a review on the problem of immune checkpoint inhibitor myocarditis, as well as the results of a systematic analysis of PubMed database publications.
About the Authors
E. A. Kushnareva
Almazov National Medical Research Center
Russian Federation
St. Petersburg.
Competing Interests: No.
Russian Federation
St. Petersburg.
Competing Interests: No.
O. M. Moiseeva
Almazov National Medical Research Center
Russian Federation
St. Petersburg.
Competing Interests: No.
Russian Federation
St. Petersburg.
Competing Interests: No.
References
1. Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: 15. An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29-39. doi:10.1016/j.intimp.2018.06.001.
2. Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med . 2015;13:211. doi:10.1186/s12916-015-0455-8.
3. Ganatra S, Neilan TG. Immune Checkpoint Inhibitor-Associated Myocarditis. The Onco- 17. logist. 2018;23:879-86. doi:10.1634/theoncologist.2018-0130.
4. Gallegos C, Rottmann D, Nguyen VQ, et al. Myocarditis with checkpoint inhibitor immunotherapy: case report of late gadolinium enhancement on cardiac magnetic 18. resonance with pathology correlate. Eur Heart J Case Rep. 2019;3(1):yty149. doi:10.1093/ehjcr/yty149.
5. McDowall LM, Fernando SL, Ange N, et al. Immune Checkpoint Inhibitor Mediated 19. myocarditis and ventricular tachycardia storm. HeartRhythm Case Rep. 2019;5(10):497-500. doi:10.1016/j.hrcr.2019.06.006.
6. Lyon AR, Yousaf N, Battisti NML, et al. Immune checkpoint inhibitors and cardiovascular 20. toxicity. Lancet Oncol. 2018;19:447-58. doi:10.1016/S1470-2045(18)30457-1.
7. Chen D. S., Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity. 2013;39:1-10. doi:10.1016/j.immuni.2013.07.012. 21.
8. Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58-67. doi:10.1182/blood-2017-06-741033.
9. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing 22. tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31:616-22. doi:10.1200/JCO.2012.44.6112.
10. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in pa- 23. tients with metastatic melanoma. N Engl J Med. 2010;363:711-23. doi:10.1056/NEJMoa1003466.
11. Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naive patients with 24. advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33:1191-6. doi:10.1200/JCO.2014.56.6018.
12. Chinai JM, Janakiram M, Chen F, et al. New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci. 2015;36:587-95. doi:10.1016/j.tips.2015.06.005.
13. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2017;377(14):1345-56. doi:10.1056/NEJMoa1709684.
14. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. European Journal of Cancer. 2016;54:139-48. doi:10.1016/j.ejca.2015.11.016.
15. Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8:e53745. doi:10.1371/journal.pone.0053745.
16. Yun S, Vincelette ND, Mansour I, et al. Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare butlife threatening complication. Case Rep Oncol Med. 2015;2015:1-5. doi:10.1155/2015/794842.
17. Frigeri M, Meyer P, Banfi C, et al. Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists. Case Rep Canadian Journal of Cardiology. 2018;34:92. e1-92.e3. doi:10.1016/j.cjca.2017.09.025.
18. Geisler BP, Raad RA, Esaian D, et al. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer. 2015;3:4. doi:10.1186/s40425-015-0048-2.
19. Ederhy S, Cautela J, Ancedy Y, et al. Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors. JACC Cardiovasc Imaging 2018;11(8):1187-90. doi:10.1016/j.jcmg.2017.11.036.
20. Hu YB, Zhang Q, Li HJ, et al. Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2017;6:8-20. doi:10.21037/tlcr.2017.12.10.
21. Cho J, Kim HS, Ku BM, et al. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. Journal of Clinical Oncology. 2019;37(24):2162-70. doi:10.1200/JCO.2017.77.3184.
22. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749-55. doi:10.1056/NEJMoa1609214.
23. Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391:933. doi:10.1016/S0140-6736(18)30533-6.
24. Liu E, Guha A, Jia K, et al. Cardiogenic shock in a patient being treated with atezolizumab for metastatic non-small cell lung cancer. Lung Cancer. 2017;114:106-107. doi:10.1016/j.lungcan.2017.07.028.
25. Laubli H, Balmelliet C, Bossard M, et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. Journal for ImmunoTherapy of Cancer. 2015;3:11. doi:10.1186/s40425-015-0057-1.
26. Fessas P, Possamai LA, Clark J, et al. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology. 2020;159(2):167-77. doi:10.1111/imm.13141.
27. Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020;52(1):17-35. doi:10.1016/j.immuni.2019.
Review
For citations:
Kushnareva E.A., Moiseeva O.M. Immune checkpoint inhibitor myocarditis: a systematic case study. Russian Journal of Cardiology. 2020;25(11):3910. (In Russ.) https://doi.org/10.15829/29/1560-4071-2020-3910
Views:
938
Email this article 